Is Tirzepatide a GLP-1 or GLP-2?

Tirzepatide is neither a GLP-2 drug nor a pure GLP-1 drug. It is a dual GIP and GLP-1 receptor agonist, meaning it activates two incretin receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It has no meaningful activity at the GLP-2 receptor.

That single fact answers most of the confusion behind searches like "is tirzepatide a glp 2" and "tirzepatide glp." The GLP-2 receptor belongs to a completely different hormone system, and the two should not be mixed up.

What Receptors Does Tirzepatide Actually Target?

Tirzepatide binds to the GIP receptor and the GLP-1 receptor. The GLP-1 side is what slows stomach emptying and reduces appetite. The GIP side adds effects on insulin secretion and fat metabolism that a GLP-1-only drug does not produce.

Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. The active molecule is the same in both products; only the approved indication and labeling differ.

One clarification that helps: GLP-1 is not the same as tirzepatide. GLP-1 is both a natural hormone and a drug class. Tirzepatide is a synthetic peptide that mimics GLP-1 and GIP simultaneously, which is why researchers file it under "dual agonist" rather than "GLP-1."

GLP-1 vs. GLP-2: Two Very Different Hormones

GLP-1 and GLP-2 come from the same parent gene, but they act in different tissues and do different jobs. That is the entire reason a GLP-2 question does not apply to a weight-management drug.

Hormone / Receptor	Where It Acts	Main Effects	Does Tirzepatide Hit It?
GLP-1	Pancreas, brain, gut, heart	Insulin release when glucose is high, slower gastric emptying, reduced appetite	Yes — one of its two targets
GIP	Pancreas, fat tissue, brain	Enhanced insulin secretion, effects on fat metabolism	Yes — its second target
GLP-2	Intestinal lining	Growth and repair of the gut lining, reduced intestinal permeability	No
Glucagon receptor	Liver	Raises blood glucose and increases energy expenditure	No (retatrutide does)

GLP-2 exists to maintain the lining of the small intestine. The only FDA-approved GLP-2 analog is teduglutide (Gattex), used for short bowel syndrome, a condition in which the gut cannot absorb enough nutrients.

Tirzepatide does not activate the GLP-2 receptor, so the answer to "is tirzepatide a GLP-2" is a straightforward no.

Is There Such a Thing as a GLP-3?

No. There is no GLP-3 receptor, no GLP-3 hormone, and no GLP-3 drug class. The label circulates in search results and social posts, but it is not part of accepted pharmacology.

Most "glp-3 vs tirzepatide" or "glp 3 vs tirzepatide" comparisons are really about retatrutide, an investigational triple agonist that targets GIP, GLP-1, and the glucagon receptor. Glucagon is not GLP-3 — it is a separate hormone with its own receptor.

Another nearby question is is ipamorelin a glp-1, and the answer is also no. Ipamorelin is a growth hormone secretagogue that works through ghrelin receptors and has nothing to do with incretin signaling.

How Tirzepatide Compares With Other Incretin Drugs

Receptor targets are the clearest way to tell these medications apart. The table below shows what each one activates.

Compound	Receptors Activated	Class	FDA-Approved for Weight Loss?
Semaglutide (Ozempic, Wegovy)	GLP-1	Single agonist	Wegovy yes; Ozempic no
Tirzepatide (Mounjaro, Zepbound)	GIP + GLP-1	Dual agonist	Zepbound yes; Mounjaro no
Liraglutide (Victoza, Saxenda)	GLP-1	Single agonist	Saxenda yes; Victoza no
Retatrutide	GIP + GLP-1 + glucagon	Triple agonist	No — still investigational

Head-to-head data is why tirzepatide vs semaglutide which is better for weight loss stays one of the most searched questions in this category. In the SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide at the doses studied, though individual results vary widely.

Does the "Dual Agonist" Label Change Safety or Dosing?

It changes how side effects are explained more than anything else. Nausea, vomiting, diarrhea, and constipation come mainly from GLP-1 receptor activation, and they often ease as the body adjusts during dose escalation.

Tirzepatide is not the same as Ozempic. Ozempic contains semaglutide, a GLP-1-only agonist, so the two are related but not interchangeable without a prescriber's guidance.

Dosing questions trip people up constantly. The answer to how many mg is 50 units of tirzepatide depends entirely on the concentration of the vial or pen, because units measure volume, not milligrams. Fifty units equals 0.5 mL, which is 2.5 mg in a 5 mg/mL product and 5 mg in a 10 mg/mL product — so always read the label rather than assuming.

Brand-name tirzepatide is FDA-approved for type 2 diabetes and for chronic weight management, but the answer to is tirzepatide fda approved is no for compounded copies. For compounded products, the honest answer to is compound tirzepatide safe is that it depends on the pharmacy, the source of the raw ingredient, and state oversight.

Key Takeaways

• Tirzepatide is a dual GIP and GLP-1 receptor agonist, not a GLP-1 drug alone.
• Tirzepatide does not activate the GLP-2 receptor, and GLP-2 drugs treat short bowel syndrome instead.
• GLP-3 does not exist as a receptor or a drug class; the term usually refers to the investigational triple agonist retatrutide.
• GLP-1 is a hormone and a drug class, while tirzepatide is a peptide that mimics GLP-1 and GIP together.

None of this is medical advice. Anyone considering tirzepatide, semaglutide, or a compounded alternative should review their history, current medications, and risk factors with a licensed healthcare professional before starting or switching treatment.

COMMON QUESTIONS

Frequently Asked Questions

Is tirzepatide a GLP-1 or GLP-2?

Tirzepatide is neither one in isolation. It is a dual GIP and GLP-1 receptor agonist, so it activates the GLP-1 receptor along with the GIP receptor. It has no meaningful activity at the GLP-2 receptor, which controls intestinal growth and repair rather than appetite or blood sugar.

What is GLP-3, and is tirzepatide one?

There is no GLP-3 receptor or GLP-3 drug class. The term is a mislabel that usually points to retatrutide, an investigational triple agonist targeting GIP, GLP-1, and the glucagon receptor. Tirzepatide is a dual agonist, not a triple agonist, and glucagon is not part of the GLP family.

Is tirzepatide the same as Ozempic?

No. Ozempic contains semaglutide, which activates only the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1. Tirzepatide is sold as Mounjaro and Zepbound, and the two drugs are not interchangeable without guidance from a prescriber.